- Home
- HUYA vs STRO Comparison
HUYA vs STRO Comparison
Compare HUYA & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUYA | STRO |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | China | United States |
| Employees | N/A | 133 |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 572.2M | 491.0M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | HUYA | STRO |
|---|---|---|
| Price | $2.25 | $31.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $3.50 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 1.3M | 265.8K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | ★ 81.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.08 | N/A |
| Revenue Next Year | $6.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.21 | $0.67 |
| 52 Week High | $4.93 | $43.85 |
Technical Indicators
Market Signals| Indicator | HUYA | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 24.90 | 54.99 |
| Support Level | N/A | $23.53 |
| Resistance Level | $3.34 | $43.85 |
| Average True Range (ATR) | 0.08 | 2.89 |
| MACD | -0.01 | 0.56 |
| Stochastic Oscillator | 2.04 | 90.92 |
Price Performance
Historical ComparisonAbout HUYA HUYA Inc. American depositary shares each representing one ordinary share
Huya officially became independent in 2016 and is headquartered in Guangzhou. It operates a live streaming platform focused on games, esports, and interactive entertainment, and also provides game-related services such as distribution and in-game item sales. Its main livestreaming platforms include Huya Live in China and Nimo TV outside of China. Huya is a subsidiary of Tencent, which owned 67% of its equity stake and held 95% of the voting power, as of the end of 2025.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.